Sun Pharma Advanced Research Company Ltd Hits Intraday High with 10.81% Surge

Intraday Trading Highlights

The stock demonstrated strong momentum throughout the trading session, reaching an intraday peak of Rs 135, marking a 6.89% rise from its previous close. This surge contributed to an overall day change of 10.81%, a notable outperformance compared to the Sensex’s modest gain of 0.26% on the same day. The stock’s performance also outpaced the Pharmaceuticals & Biotechnology sector by 6.48%, underscoring its relative strength within the industry.

Sun Pharma Advanced Research Company Ltd has now recorded gains for two consecutive trading days, accumulating a 7.78% return over this period. This recent uptick contrasts with its longer-term performance, which has been subdued relative to the benchmark index.

Moving Averages and Technical Positioning

From a technical perspective, the stock is trading above its 5-day and 20-day moving averages, signalling short-term positive momentum. However, it remains below its 50-day, 100-day, and 200-day moving averages, indicating that medium to long-term trends have yet to fully align with the recent strength. This mixed technical picture suggests that while immediate trading activity is bullish, broader trend confirmation is pending.

Market Context and Sector Comparison

The broader market environment on 1 Feb 2026 was positive, with the Sensex opening 119.19 points higher and trading at 82,487.48, up 0.26%. The index remains 4.45% below its 52-week high of 86,159.02. Mega-cap stocks led the market gains, supporting the overall positive sentiment. Despite the Sensex trading below its 50-day moving average, the 50DMA itself is positioned above the 200DMA, reflecting a generally constructive medium-term market trend.

Within this context, Sun Pharma Advanced Research Company Ltd’s outperformance is particularly notable. Its 1-day gain of 11.08% starkly contrasts with the Sensex’s 0.25% rise, while its 1-week return of 12.56% also significantly exceeds the Sensex’s 1.15% gain. Over the past month, the stock has delivered a 4.35% return, outperforming the Sensex’s negative 2.59% performance. Even over three months, the stock posted a positive 2.37% return against the Sensex’s decline of 2.28%.

Longer-Term Performance Overview

Despite the recent positive momentum, Sun Pharma Advanced Research Company Ltd’s longer-term returns remain under pressure relative to the Sensex. The stock has declined 11.20% over the past year, while the Sensex has gained 7.45% in the same period. Year-to-date, the stock has posted a 4.35% gain, outperforming the Sensex’s negative 3.22% return.

Over a three-year horizon, the stock has fallen 27.12%, contrasting with the Sensex’s robust 38.62% gain. Similarly, five-year and ten-year returns for the stock are negative at -21.53% and -54.68% respectively, while the Sensex has delivered 78.19% and 231.63% gains over these periods. These figures highlight the stock’s historical challenges in matching broader market growth despite recent intraday strength.

Mojo Score and Market Capitalisation Grade

Sun Pharma Advanced Research Company Ltd currently holds a Mojo Score of 1.0, categorised as a Strong Sell, reflecting cautious sentiment based on its fundamentals and momentum. This rating was downgraded from Sell on 1 Feb 2024. The company’s Market Capitalisation Grade stands at 3, indicating a mid-tier market cap relative to its peers in the Pharmaceuticals & Biotechnology sector.

Trading Activity and Immediate Catalysts

The stock’s strong intraday performance on 1 Feb 2026 appears to be driven by active trading interest and positive momentum within the Pharmaceuticals & Biotechnology sector. The outperformance relative to both the Sensex and sector peers suggests that the stock is currently attracting attention for its short-term price action. The rise above short-term moving averages supports this view, signalling a shift in trading dynamics during the session.

Summary of Recent Price Movements

Sun Pharma Advanced Research Company Ltd’s recent price trajectory shows a notable recovery in the short term, with the stock gaining 12.56% over the past week and 4.35% over the past month. This contrasts with the Sensex’s more modest gains and occasional declines over the same periods. The stock’s ability to outperform the benchmark index and sector peers in the immediate term highlights a phase of renewed trading interest and price strength.

However, the stock’s position below longer-term moving averages and its historical underperformance relative to the Sensex indicate that this rally is occurring against a backdrop of broader challenges. Investors and market participants will likely continue to monitor the stock’s price action and technical signals closely in the coming sessions.

Sector and Market Environment

The Pharmaceuticals & Biotechnology sector remains a key focus area within the broader market, with several stocks exhibiting varied performance patterns. Sun Pharma Advanced Research Company Ltd’s strong intraday gains on 1 Feb 2026 stand out amid a market led by mega-cap stocks, which have been driving the Sensex’s modest gains. The sector’s overall performance and the stock’s relative strength contribute to a nuanced market picture on this trading day.

Conclusion

On 1 Feb 2026, Sun Pharma Advanced Research Company Ltd demonstrated a strong intraday rally, reaching a high of Rs 135 and delivering a day change of 10.81%. This performance significantly outpaced the Sensex and sector averages, supported by gains over the last two days and positive short-term technical indicators. While the stock’s longer-term returns remain subdued relative to the benchmark, the immediate trading session highlighted renewed momentum and active market participation.

The stock’s Mojo Score of 1.0 and Market Cap Grade of 3 provide additional context to its current standing within the Pharmaceuticals & Biotechnology sector. Market participants will be watching subsequent sessions to assess whether this intraday strength can be sustained or if it represents a short-term trading phenomenon.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →